Bioelectronics Corp (BIEL)

[srinsocal]

"data published in a peer-reviewed journal"

Hindawi is a well respected Peer-Reviewed Journal. This is an ActiPatch Study but as most BIEL followers know by now ActiPatch and RecoveryRX are the same device.

Hindawi
Pain Research and Management

A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel
OTC Neuromodulation Therapy
Received 25 June 2019; Accepted 7 September 2019; Published 30 September 2019

"Results. Seven days after initial treatment, the average pain was reduced to 2.9, a 65% pain reduction for the study subjects. At the 6-month measurement, the average pain was 3.3, a 60% pain reduction from baseline."

"A decline in treatment effectiveness is commonly associated
with long-term use of pharmacological treatments, for example, with NSAIDS [26] and opioids, owing to tolerance [27].The goal of this prospective study is to assess the durability of treatment effectiveness for the PSWT medical device over a 6-month period".

Table 3: Analgesic medications used by the study sample.
Analgesics Fraction of users (%)
NSAIDS (e.g., ibuprofen) 43
Paracetamol 61
Weak opioids (e.g., codeine) 25
Strong opioids (e.g., hydrocodone) 11
Tramadol or equivalent 8
Pregabalin (e.g., Lyrica) 8
Amitriptyline 17
Topical opioid (e.g., morphine) 8
Topical NSAIDS (e.g., Voltarol) 21
Gabapentin 2
Other 4
No analgesics 5

https://downloads.hindawi.com/journals/prm/2019/3154194.pdf

Does anyone really think that cash strapped BIEL is spending money hiring a Centers for Medicare/Medicaid Services Medical Biller/Coder without confirming that the 'No Pain' bill will apply to their products?